PL1713459T3 - Zastosowanie agonistów receptorów sfingozyno-1-fosforanu (S1P) do leczenia chorób zwyrodnieniowych mózgu - Google Patents
Zastosowanie agonistów receptorów sfingozyno-1-fosforanu (S1P) do leczenia chorób zwyrodnieniowych mózguInfo
- Publication number
- PL1713459T3 PL1713459T3 PL04804037T PL04804037T PL1713459T3 PL 1713459 T3 PL1713459 T3 PL 1713459T3 PL 04804037 T PL04804037 T PL 04804037T PL 04804037 T PL04804037 T PL 04804037T PL 1713459 T3 PL1713459 T3 PL 1713459T3
- Authority
- PL
- Poland
- Prior art keywords
- sphingosine
- phosphate
- treatment
- receptor agonists
- degenerative diseases
- Prior art date
Links
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title abstract 3
- 210000004556 brain Anatomy 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940124118 AMPA receptor agonist Drugs 0.000 abstract 1
- 239000000774 AMPA receptor agonist Substances 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002664 nootropic agent Substances 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329498.0A GB0329498D0 (en) | 2003-12-19 | 2003-12-19 | Organic compounds |
| PCT/EP2004/014436 WO2005058295A2 (en) | 2003-12-19 | 2004-12-17 | Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| EP04804037A EP1713459B1 (en) | 2003-12-19 | 2004-12-17 | Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1713459T3 true PL1713459T3 (pl) | 2010-12-31 |
Family
ID=30776138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04804037T PL1713459T3 (pl) | 2003-12-19 | 2004-12-17 | Zastosowanie agonistów receptorów sfingozyno-1-fosforanu (S1P) do leczenia chorób zwyrodnieniowych mózgu |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20080139662A1 (pl) |
| EP (2) | EP1713459B1 (pl) |
| JP (2) | JP2007514698A (pl) |
| KR (2) | KR101342244B1 (pl) |
| CN (2) | CN101791406B (pl) |
| AT (1) | ATE474569T1 (pl) |
| AU (1) | AU2004298760B2 (pl) |
| BR (1) | BRPI0417203A (pl) |
| CA (2) | CA2545503C (pl) |
| DE (1) | DE602004028286D1 (pl) |
| ES (2) | ES2444717T3 (pl) |
| GB (1) | GB0329498D0 (pl) |
| HK (1) | HK1097458A1 (pl) |
| MX (1) | MXPA06006924A (pl) |
| PL (1) | PL1713459T3 (pl) |
| PT (1) | PT1713459E (pl) |
| RU (1) | RU2379030C2 (pl) |
| WO (1) | WO2005058295A2 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3103448B1 (en) * | 2006-09-26 | 2019-07-03 | Novartis Ag | Pharmaceutical compositions comprising an s1p modulator |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| WO2010011316A1 (en) | 2008-07-23 | 2010-01-28 | Arena Pharmaceuticals, Inc. | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
| MX2011002199A (es) | 2008-08-27 | 2011-05-10 | Arena Pharm Inc | Derivados de acidos triciclicos substituidos como agonistas del receptor s1p1 utiles en el tratamiento de trastornos autoinmunes e inflamatorios. |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US20120128666A1 (en) * | 2009-06-24 | 2012-05-24 | Lpath, Inc. | Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| AR077969A1 (es) * | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
| KR101928299B1 (ko) | 2010-03-01 | 2018-12-12 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포로부터 유래된 세포의 정제 방법 |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| CN105143446B (zh) | 2011-12-22 | 2020-11-03 | 詹森生物科技公司 | 人胚胎干细胞分化成单一激素胰岛素阳性细胞 |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| CN105705634A (zh) | 2012-12-31 | 2016-06-22 | 詹森生物科技公司 | 用于分化成胰腺内分泌细胞的人多能细胞的悬浮和群集 |
| RU2768963C2 (ru) | 2012-12-31 | 2022-03-25 | Янссен Байотек, Инк. | Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| WO2016112075A1 (en) | 2015-01-06 | 2016-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| AU2018222747A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| EP4011397A4 (en) * | 2019-08-07 | 2023-09-27 | National University Corporation Tokyo Medical and Dental University | AGENTS FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT |
| MX2022005084A (es) | 2019-10-31 | 2022-05-26 | Escape Bio Inc | Formas sólidas de un modulador del receptor s1p a. |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3154742B2 (ja) * | 1991-04-30 | 2001-04-09 | 日本石油化学株式会社 | 哺乳類の動脈硬化症治療剤 |
| EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| ATE211726T1 (de) | 1994-08-22 | 2002-01-15 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| ATE212227T1 (de) * | 1995-02-15 | 2002-02-15 | Takeda Chemical Industries Ltd | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta- amyloid-protein |
| DE19513630A1 (de) * | 1995-04-05 | 1996-10-10 | Schering Ag | Neue Verwendung von AMPA-Agonisten |
| CZ285953B6 (cs) * | 1995-12-28 | 1999-12-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Vnější přípravek pro topické podání |
| AU3641597A (en) * | 1996-06-21 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions comprising r-ibuprofen |
| ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
| EP2030614A1 (en) * | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| KR100551931B1 (ko) | 1997-04-04 | 2006-02-16 | 미츠비시 웰파마 가부시키가이샤 | 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체 |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| ES2332390T3 (es) * | 1999-02-26 | 2010-02-03 | Maas Biolab, Llc | Composicion farmaceutica cerebroespinal y vascular y proceso para prepararla. |
| US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| CN1328387C (zh) | 2000-07-13 | 2007-07-25 | 三共株式会社 | 氨基醇衍生物 |
| AU2001285331B2 (en) * | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| US20030013692A1 (en) * | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
| WO2002076995A2 (en) * | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| WO2003011269A1 (de) * | 2001-07-31 | 2003-02-13 | Lothar Saiger | Mittel zur behandlung der symptome von demenzerkrankungen enthalten ein zusatzliches lokalanasthetikum |
| EP1431284B1 (en) * | 2001-09-27 | 2007-11-21 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| ATE463478T1 (de) | 2001-09-27 | 2010-04-15 | Kyorin Seiyaku Kk | Diaryletherderivat, dessen additionssalz und immunosuppressivum |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| AU2003207567B2 (en) * | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| AU2003233119A1 (en) | 2002-05-08 | 2003-11-11 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
| GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| JP4166218B2 (ja) * | 2002-09-13 | 2008-10-15 | ノバルティス アクチエンゲゼルシャフト | アミノ−プロパノール誘導体 |
| US6776328B2 (en) | 2002-09-17 | 2004-08-17 | The Boeing Company | Radiation assisted friction welding |
| US20060046979A1 (en) * | 2002-09-24 | 2006-03-02 | Foster Carolyn A | Organic compounds |
| ATE547395T1 (de) * | 2003-04-30 | 2012-03-15 | Novartis Pharma Gmbh | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors |
| WO2005002559A2 (en) * | 2003-06-24 | 2005-01-13 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
| WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
-
2003
- 2003-12-19 GB GBGB0329498.0A patent/GB0329498D0/en not_active Ceased
-
2004
- 2004-12-17 CA CA2545503A patent/CA2545503C/en not_active Expired - Fee Related
- 2004-12-17 RU RU2006125744/15A patent/RU2379030C2/ru not_active IP Right Cessation
- 2004-12-17 EP EP04804037A patent/EP1713459B1/en not_active Not-in-force
- 2004-12-17 AT AT04804037T patent/ATE474569T1/de active
- 2004-12-17 JP JP2006544366A patent/JP2007514698A/ja active Pending
- 2004-12-17 KR KR1020127019200A patent/KR101342244B1/ko not_active IP Right Cessation
- 2004-12-17 DE DE602004028286T patent/DE602004028286D1/de active Active
- 2004-12-17 CA CA2792467A patent/CA2792467A1/en not_active Abandoned
- 2004-12-17 CN CN2010101454323A patent/CN101791406B/zh not_active Expired - Fee Related
- 2004-12-17 KR KR1020067011896A patent/KR101232934B1/ko not_active IP Right Cessation
- 2004-12-17 BR BRPI0417203-5A patent/BRPI0417203A/pt not_active IP Right Cessation
- 2004-12-17 EP EP09177200.4A patent/EP2213285B1/en not_active Not-in-force
- 2004-12-17 WO PCT/EP2004/014436 patent/WO2005058295A2/en active Application Filing
- 2004-12-17 AU AU2004298760A patent/AU2004298760B2/en not_active Ceased
- 2004-12-17 ES ES09177200.4T patent/ES2444717T3/es active Active
- 2004-12-17 ES ES04804037T patent/ES2348569T3/es active Active
- 2004-12-17 US US10/583,106 patent/US20080139662A1/en not_active Abandoned
- 2004-12-17 CN CN2004800378611A patent/CN1893934B/zh not_active Expired - Fee Related
- 2004-12-17 MX MXPA06006924A patent/MXPA06006924A/es active IP Right Grant
- 2004-12-17 PT PT04804037T patent/PT1713459E/pt unknown
- 2004-12-17 PL PL04804037T patent/PL1713459T3/pl unknown
-
2007
- 2007-03-29 HK HK07103403.8A patent/HK1097458A1/xx not_active IP Right Cessation
-
2010
- 2010-09-17 US US12/884,953 patent/US8519006B2/en not_active Expired - Fee Related
-
2011
- 2011-04-28 JP JP2011100640A patent/JP5469122B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-18 US US13/920,329 patent/US20130281541A1/en not_active Abandoned
- 2013-12-02 US US14/093,975 patent/US20140162964A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1097458A1 (en) | Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases | |
| WO2004010987A3 (en) | Use of s1p receptor agonists in heart diseases | |
| PL375053A1 (pl) | Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych | |
| MXPA04004370A (es) | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. | |
| TW200716641A (en) | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | |
| HK1094421A1 (en) | (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist | |
| IL165257A0 (en) | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia | |
| WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
| AU2003249983A1 (en) | Piperidines useful for the treatment of central nervous system disorders | |
| HK1097258A1 (en) | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | |
| IL188789A0 (en) | Formulation and method for administration of ophthalmologically active agents | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| AU2003223579A1 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease | |
| MXPA05013733A (es) | 2-aminobenzotiazoles como agonistas inversos del receptor de cb1. | |
| WO2007023310A3 (en) | Stimulation of neurogenesis with help of alk inhibitors | |
| MX2009002573A (es) | Aparato quirurgico para osteosintesis. | |
| AU2002335027A1 (en) | Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors | |
| WO2008032222A3 (en) | Treatment of vertigo with acetyl-l-leucine | |
| EP1642576A3 (en) | Methods, kits and compositions for using pyrrole derivatives to combat anxiety | |
| WO2007015173A3 (en) | Inflammation | |
| AU2002365288A1 (en) | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | |
| WO2007012870A3 (en) | Use of nefopam for the treatment of affective disorders | |
| RS20050393A (en) | Improved process for the preparation of 1,3-substituted indenes | |
| AU2003284068A1 (en) | Substituted aminoquinuclidine compounds and their use as delta-opioid receptor ligands | |
| UA85198C2 (ru) | Производные морфолина как ингибиторы повторного поглощения норэпинефрина |